One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis.
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
24 Mar 2022
24 Mar 2022
Historique:
received:
17
08
2021
accepted:
17
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
29
3
2022
Statut:
epublish
Résumé
In Germany, the first case of coronavirus disease 2019 (COVID-19) was registered on 28 January 2020. By February 2021, the third wave of the pandemic began. So far, only few data are available on the SARS-CoV-2 prevalence and the clinical impact of an infection in patients with cystic fibrosis (CF). From February 2020 until March 2021, we screened 156 CF patients for anti-SARS-CoV-2 IgG antibodies (serology) and the presence of SARS-CoV-2 in deep throat saliva or nasopharyngeal swabs (molecular testing). From patients with confirmed SARS-CoV-2 infection, we recorded symptoms and collected clinical data. In total, 13 patients (8.3%) were tested positive for SARS-CoV-2 infection, most of them during the second and the beginning third wave of the pandemic. Ten positive tested patients described symptoms linked to COVID-19. The most common symptom was cough followed by fatigue and headache. SARS-CoV-2 infection did not impair lung function. No positive tested patient needed to be hospitalized. SARS-CoV-2 infections in patients with CF are not as rare as initially anticipated, as frequent testing revealed. However, infected patients did not experience more severe clinical courses or worse clinical outcome. Our observation is in line with published reports indicating that individuals with CF are not at higher risk for severe COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
In Germany, the first case of coronavirus disease 2019 (COVID-19) was registered on 28 January 2020. By February 2021, the third wave of the pandemic began. So far, only few data are available on the SARS-CoV-2 prevalence and the clinical impact of an infection in patients with cystic fibrosis (CF).
METHODS
METHODS
From February 2020 until March 2021, we screened 156 CF patients for anti-SARS-CoV-2 IgG antibodies (serology) and the presence of SARS-CoV-2 in deep throat saliva or nasopharyngeal swabs (molecular testing). From patients with confirmed SARS-CoV-2 infection, we recorded symptoms and collected clinical data.
RESULTS
RESULTS
In total, 13 patients (8.3%) were tested positive for SARS-CoV-2 infection, most of them during the second and the beginning third wave of the pandemic. Ten positive tested patients described symptoms linked to COVID-19. The most common symptom was cough followed by fatigue and headache. SARS-CoV-2 infection did not impair lung function. No positive tested patient needed to be hospitalized.
CONCLUSIONS
CONCLUSIONS
SARS-CoV-2 infections in patients with CF are not as rare as initially anticipated, as frequent testing revealed. However, infected patients did not experience more severe clinical courses or worse clinical outcome. Our observation is in line with published reports indicating that individuals with CF are not at higher risk for severe COVID-19.
Identifiants
pubmed: 35331203
doi: 10.1186/s12890-022-01900-8
pii: 10.1186/s12890-022-01900-8
pmc: PMC8943512
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101Informations de copyright
© 2022. The Author(s).
Références
Lancet. 2016 Nov 19;388(10059):2519-2531
pubmed: 27140670
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Cyst Fibros. 2021 Jan;20(1):25-30
pubmed: 33309057
BMC Pulm Med. 2021 May 20;21(1):173
pubmed: 34016096
Am J Epidemiol. 1978 Jan;107(1):71-6
pubmed: 623091
Lancet Respir Med. 2020 May;8(5):e35-e36
pubmed: 32304639
PLoS One. 2021 May 13;16(5):e0251527
pubmed: 33984027
Cochrane Database Syst Rev. 2020 Aug 26;8:CD013705
pubmed: 32845525
J Cyst Fibros. 2020 May;19(3):355-358
pubmed: 32376098
Clin Microbiol Infect. 2021 Mar;27(3):470.e1-470.e9
pubmed: 33221432